Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Carcinoma, Medullary × rovalpituzumab tesirine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Small Cell Lung Carcinoma 2 Neoplasms 1 Melanoma 1 Glioblastoma 1 Carcinoma, Medullary 1

Interventions

vandetanib 3 selpercatinib 2 rovalpituzumab tesirine 1 pralsetinib 1 Peripheral Blood Stem Cell Transplantation 1 Indium 1 Imatinib Mesylate 1 Filgrastim 1 Doxorubicin 1 Dexamethasone 1 Dacarbazine 1 Capecitabine 1 Calcium Aluminosilicate 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated

200 enrolled 21 charts

CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡